Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,885 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,373)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06055075 | A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 21 | Hoffmann-La RocheINDUSTRY | 6 | Sep 29, 2026 | clinicaltrials |
| NCT01947140 | Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies(PDX+Romi) | terminated | Phase 1 / Phase 2 | 57 | Jennifer AmengualOTHER | 1 | Sep 16, 2026 |
| clinicaltrials |
| NCT04649073 | Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05262673 | NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL | terminated | Phase 1 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05277753 | NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL | terminated | Phase 1 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07556757 | A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia | terminated | Phase 1 | 4 | ImmunityBio, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06622226 | A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | terminated | Phase 1 | 2 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03598608 | Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) | terminated | Phase 1 / Phase 2 | 137 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Jul 28, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06028373 | A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas | terminated | Phase 1 | 38 | Antengene Biologics LimitedINDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05828589 | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | terminated | Phase 1 | 51 | BeOne MedicinesINDUSTRY | 4 | Jul 14, 2026 | clinicaltrials |
| NCT04318327 | BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma | terminated | Phase 1 | 96 | Novartis PharmaceuticalsINDUSTRY | 4 | Jul 9, 2026 | clinicaltrials |
| NCT04855136 | Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma(KarMMa-7) | terminated | Phase 1 | 21 | CelgeneINDUSTRY | 2 | Jul 9, 2026 | clinicaltrials |
| NCT06120504 | A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers | terminated | Phase 1 | 22 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | Jul 6, 2026 | clinicaltrials |
| NCT06254495 | A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers | terminated | Phase 1 | 58 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 6 | Jul 6, 2026 | clinicaltrials |
| NCT05255601 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma(RELATIVITY-069) | terminated | Phase 1 / Phase 2 | 5 | Bristol-Myers SquibbINDUSTRY | 7 | Jun 26, 2026 | clinicaltrials |
| NCT05498545 | Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 8 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05515406 | A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL | terminated | Phase 1 | 9 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT01421927 | Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma(REVALLO) | terminated | Phase 1 | 13 | University Hospital, BordeauxOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04824794 | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 130 | GenmabINDUSTRY | 20 | May 19, 2026 | clinicaltrials |
| NCT03808610 | Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers | terminated | Phase 1 | 6 | PfizerINDUSTRY | 2 | May 8, 2026 | clinicaltrials |
| NCT05896163 | A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.(MAPtivate-6) | terminated | Phase 1 / Phase 2 | 40 | PfizerINDUSTRY | 4 | May 6, 2026 | clinicaltrials |
| NCT06163898 | A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 | 4 | CelgeneINDUSTRY | 2 | Apr 21, 2026 | clinicaltrials |
| NCT05605119 | First in Human, Dose Escalation, Dose Expansion Study of AUR105(SURYA-1) | terminated | Phase 1 | 17 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05607199 | A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics(BHARAT-1) | terminated | Phase 1 | 27 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05983965 | Study of Tazemetostat in Lymphoid Malignancies | terminated | Phase 1 | 6 | University of Alabama at BirminghamOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06088654 | Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 23 | Innate PharmaINDUSTRY | 3 | Apr 14, 2026 | clinicaltrials |
| NCT04853329 | Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma | terminated | Phase 1 | 7 | Conjupro Biotherapeutics, Inc.INDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT02681302 | Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence(CPIT001) | terminated | Phase 1 / Phase 2 | 46 | Hackensack Meridian HealthOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05618366 | Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma | terminated | Phase 1 | 3 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04903197 | Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma | terminated | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 7 | Apr 1, 2026 | clinicaltrials |
| NCT03547115 | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML | terminated | Phase 1 | 84 | MEI Pharma, Inc.INDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT03590574 | Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma | terminated | Phase 1 / Phase 2 | 20 | Autolus LimitedINDUSTRY | 2 | Mar 16, 2026 | clinicaltrials |
| NCT05994157 | Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma | terminated | Phase 1 | 1 | Y-mAbs TherapeuticsINDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05721222 | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) | terminated | Phase 1 / Phase 2 | 42 | GenmabINDUSTRY | 2 | Mar 4, 2026 | clinicaltrials |
| NCT04362007 | A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma | terminated | Phase 1 / Phase 2 | 8 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT03779113 | An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma | terminated | Phase 1 | 69 | HutchmedINDUSTRY | 7 | Feb 18, 2026 | clinicaltrials |
| NCT03031730 | Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma | terminated | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Feb 10, 2026 | clinicaltrials |
| NCT03374085 | A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | terminated | Phase 1 / Phase 2 | 200 | CelgeneINDUSTRY | 11 | Feb 9, 2026 | clinicaltrials |
| NCT04809467 | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)(topMIND) | terminated | Phase 1 / Phase 2 | 54 | Incyte CorporationINDUSTRY | 7 | Feb 4, 2026 | clinicaltrials |
| NCT05590377 | A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma(iinnovate-3) | terminated | Phase 1 / Phase 2 | 15 | Teva Branded Pharmaceutical Products R&D LLCINDUSTRY | 7 | Jan 30, 2026 | clinicaltrials |
| NCT03215030 | A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma(iinnovate-1) | terminated | Phase 1 / Phase 2 | 272 | Teva Branded Pharmaceutical Products R&D LLCINDUSTRY | 16 | Jan 29, 2026 | clinicaltrials |
| NCT05556616 | A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma(iinnovate-2) | terminated | Phase 1 | 15 | Teva Branded Pharmaceutical Products R&D LLCINDUSTRY | 4 | Jan 29, 2026 | clinicaltrials |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 | 79 | National Cancer Institute (NCI)NIH | 2 | Jan 21, 2026 | clinicaltrials |
| NCT04425070 | A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma(TOUCH) | terminated | Phase 1 / Phase 2 | 56 | Antengene CorporationINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06106841 | TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) | terminated | Phase 1 / Phase 2 | 19 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04123418 | A Study of WVT078 in Patients With Multiple Myeloma (MM) | terminated | Phase 1 | 56 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 24, 2025 | clinicaltrials |
| NCT05336409 | A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies(ELiPSE-1) | terminated | Phase 1 | 28 | Century Therapeutics, Inc.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
Data updated 6 hours agoSource updated Sep 29, 2026source: clinicaltrials